Paul Barr, MD
At 29 months’ follow-up, frontline ibrutinib (Imbruvica) reduced the risk of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the latest findings from the phase III RESONATE-2 trial presented at the 2016 ASH Annual Meeting.
“The quality of responses in patients with CLL/SLL being treated with single-agent ibrutinib continues to improve with time,” Barr concluded. “Further, rates of treatment-limiting AEs decreased over time, and a majority of the elderly patient population in the trial remains on daily ibrutinib,” said Barr.
This article was repurposed from AJMC.com
Barr PM, Robak T, Owen CJ, et al. Updated efficacy and safety from the phase 3 RESONATE-2 study: ibrutinib as firstline treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Presented at: 58th American Society of Hematology Annual Meeting & Exposition; December 3, 2016; San Diego, CA. Abstract 234.
... to read the full story